Which pharma companies lead oncology today based on brand strength, pipeline depth, and recent regulatory momentum?

How do leading GLP-1 brands compare for obesity on efficacy, tolerability, adherence, and access?

Which companies are best positioned in obesity treatment based on current brands and late-stage pipeline?

Which pharma companies have the strongest next 12 months of pipeline catalysts across oncology, immunology, and obesity?

Which top pharma companies face the greatest loss of exclusivity risk over the next three years, and which brands are most exposed?